Holyoak, Ferguson could change FTC dynamics but face steep learning curve

If Republican nominees Melissa Holyoak of Utah and Andrew Ferguson of Virginia are confirmed, as expected, to join the Federal Trade Commission this month, they could change the dynamics of an agency that’s been under single-party control for half...

Neill Averitt

Insulin cases need a sharper focus

Hard cases are notorious for making bad law. But sometimes the easy and obvious cases can make bad law, too. Something like this seems to be going on with insulin pricing.

Current Issue: 796

FTC in the driver’s seat on vehicle-industry regulation

The Federal Trade Commission has been given enhanced powers to regulate the $620 billion car-sales and finance industry under the Dodd-Frank Wall Street Reform and Consumer Protection Act---and it...

Is innovation an antitrust innovation?

Are the effects on innovation becoming an important new criterion in government antitrust deliberations?

FTC’s Rosch predicts trouble with ACOs

Health-care providers who want to participate in the Medicare Shared Savings Program by joining together to form Accountable Care Organizations will need to police themselves carefully to avoid...

FTC sides with dental hygienists in Maine

The FTC staff told the Maine Board of Dental Examiners that its proposed rules on dental hygienists could restrict a pilot project designed to expand access to dental services in areas where no...

Second look at Lundbeck

An eight-day bench hearing held in Minneapolis, Minn., in December 2009, could have far-reaching legal implications for antitrust law, particularly regarding future pharmaceutical cases. It could...

Gilead Science vies for purchase of Pharmasset

Biotechnology firm Gilead Sciences, the leading maker of HIV drugs, has announced its plans to acquire a rival firm, Pharmasset, for $11 billion.




Access all archived issues back to 1994